BNP/PUT/ELI LILLY & CO/700/0.1/20.12.24 | Real-time Boerse Frankfurt Warrants 05:21:09 2024-06-27 EDT | ||
| 1.06 EUR | -5.36% |
|
| Current month | -52.34% | ||
| 1 month | -56.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 1.06 | -5.36% |
| 24-06-26 | 1.12 | +3.70% |
| 24-06-25 | 1.08 | -6.09% |
| 24-06-24 | 1.15 | -8.73% |
| 24-06-21 | 1.26 | -5.26% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 05:21 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC7ZJB |
| ISIN | DE000PC7ZJB9 |
| Date issued | 2024-04-09 |
| Strike | 700 $ |
| Maturity | 2024-12-20 (177 Days) |
| Parity | 10 : 1 |
| Emission price | 3.66 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.57 € |
|---|---|
| Lowest since issue | 1 € |
| Spread | 0.03 € |
| Spread % | 2.70% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
